EXPLANATION REGARDING THE PERFORMANCE OF SF2000- SONDASHI FORMULA FOR THE CURE AND TREATMENT OF HIV/AIDS

As you may be aware, I founded this medicine in the year 1999, and in 2000, I discovered that the medicine could cure and treat HIV/AIDS diseases, which have affected most of our relatives and friends the world over. The following is an analysis of both invitro (laboratory) and vivo (human and animals) tests which have been subjected to the Sondashi Formula.

In the year 2003, I handed over the herbal medicine to Dr. Patrick Chikusu of the National Aids Council, who was Chairman of the National Technical Committee, on traditional and alternative remedies, for testing. On 13th September, 2004, after carrying out the laboratory testing, Dr. Chikusu informed the Permanent Secretary of the Ministry of Health, as follows:

1. That my medicine and two other medicines from other herbalists were assessed for safety and were found to have no toxicity to normal MT4 cells and were found to be non-toxic.
2. That the medicines were tested against HIV Sub Type B and found to be efficacious, by killing HIV Sub Type B at specific dilution which is non toxic to normal MT4 cells, and
3. That the interesting finding is of great national importance; especially Sondashi Formulation from herbs of Zambia

On the 14th October 2004, Dr. S.K. Miti, the Permanent Secretary in the Ministry of Health sent me a letter, enclosing the above stated Report. It was from this preliminary finding that the late President Mwanawasa obtained funding and directed the National Aids Council to give permission to Dr. Chikusu, as Principal Investigator, to carry out further clinical observations on this herbal medicine among others. I was given ten (10) patients, whom I administered the Sondashi Formula over a period of six months. These open observational and exploratory clinical studies lasted from 17th November 2005 to 26th April 2006. My medicine was found to be the best among the three herbal medicines. Dr. Chikusu, on 4th April 2007, wrote me a letter, informing me of how my product behaved in these exploratory clinical studies. The following is what he wrote about the Sondashi Formula:

1. “Safety – There was no toxicity which can be attributed to the product.
2. Spicing – There was no commonly used anti retroviral noted in the product.
3. Efficacy – The product showed that six out of ten patients increased in CD4 cell count correspondent to viral load reduction. (See attached).
4. Clinical physical studies showed:

• Increase in body weight
• Increase in appetite
• No opportunistic infections such as Meningitis, Tuberculosis, sexually Transmitted Infections and Diarrhoea

He went on to say that “from this, it is important that further studies be made for a larger group and longer period and that he hoped that I would enter into discussion with Government to further this work.”

Since these findings of Dr. Chikusu were disputed in Zambia, I decided to take my medicine to South Africa for a second opinion. There, a prestigious Council for Science and Industrial Research (CSIR) under the sponsorship of NEPAD welcomed my medicine and carried out laboratory trials both in South Africa and the United States of America. The findings in both countries confirmed the findings by Dr. Chikusu made in Zambia, precisely their findings were as follows:

1. That SF-2000 was effective against both HIV sub-type B and sub-type C. That it is more pronounced against sub-type C, the good news being that sub-type C strain is the most relevant type found in Africa.
2. That the safety studies conducted on the mice showed that there was no toxicity which could be attributed to the product; and
3. That SF2000 attacks and kills the HIV virus irreversibly and does so without harming the CD4 cell etc.

It is from these unique findings that a combined delegation of NEPAD, CSIR and MRC of South Africa arranged to meet the Zambian team of Scientists in Lusaka to inform them of this good news and to map out the way forward, since under NEPAD which was spear-heading these investigations, Zambia was required to play a role as the owner of the biodiversity and founder of the herbal medicine.

At that meeting which took place at Anina’s Executive Lodge in Lusaka, the meeting of the South African and Zambian scientists recommended that Zambia played a part in hosting the safety clinical trials and the fundings of those clinical trials.

Zambia released K800,000,000 (KR800,000) towards these clinical trials and have chosen these to take place at Ndola Central Hospital by Tropical Disease Research Centre. It is these trials which are being awaited, once concluded positively, they will open the way for declaring the SF2000 safe for human consumption. Since the medicine has already been found to be efficacious in the laboratory (invitro) tests.

This is an important milestone to clear as it will inspire further, the governments of Zambia and South Africa, the international pharmaceutical companies and well wishers like businessmen in Zambia to offer themselves to fund the final efficacy clinical trials in vivo, in human beings, as well as studies in detecting the active ingredient in the SF2000 to boost commercialization.